CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report

Ruth-Maria Urbantat; Valentin Popper; Elisabeth Menschel; Michael Pfeilstoecker; Ernst Forjan; Alexander Nader; Caroline Sieghart; Felix Keil; Elisabeth Koller

doi:10.22541/au.159610144.47192330

loading page

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report

Ruth-Maria Urbantat,
Valentin Popper,
Elisabeth Menschel,
Michael Pfeilstoecker,
Ernst Forjan,
Alexander Nader,
Caroline Sieghart,
Felix Keil,
Elisabeth Koller

Abstract

CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar risk profile. Until now, this sub-group of AML patients had a worse overall